Jena, Germany

Albert Härtl

This inventor holds 1 USPTO granted patent. Top assignee: Wolff Cellulosics Gmbh Co. Kg. Active years: 2007.


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Albert Härtl: Innovator in Infectious Disease Treatment

Introduction

Albert Härtl is a notable inventor based in Jena, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of infectious diseases. His innovative approach involves the use of polysaccharide derivatives, showcasing his commitment to advancing healthcare solutions.

Latest Patents

Albert Härtl holds a patent for a method of treating infectious diseases with polysaccharide derivatives. This invention involves providing an alpha-glycosidically linked starch polysaccharide derivative and inhibiting the growth of infectious diseases by administering a composition that includes this derivative. The patent outlines specific chemical structures and substitutions that enhance the effectiveness of the treatment.

Career Highlights

Throughout his career, Albert has been associated with Wolff Cellulosics GmbH Co. Kg, where he has applied his expertise in developing innovative solutions for medical applications. His work has been instrumental in creating new methods that address critical health challenges.

Collaborations

Albert has collaborated with notable colleagues, including Vera Haack and Thomas Heinze. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Albert Härtl's contributions to the field of infectious disease treatment through his innovative patent demonstrate his dedication to improving healthcare. His work continues to inspire advancements in medical science and showcases the importance of innovation in addressing global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…